Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Seagen Inc.
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
CanBas Co. Ltd.
Bayer
Critical Outcome Technologies Inc.
Amgen